MSB 1.86% $1.10 mesoblast limited

Unless "Whytee" works at the FDA, there's no way for him to make...

  1. 12,097 Posts.
    lightbulb Created with Sketch. 1072
    Unless "Whytee" works at the FDA, there's no way for him to make statements like, "The FDA rejected this approach" and "According to the FDA the reason this misunderstanding occurred...", etc. The FDA doesn't make public pronouncements like that. According to the leading experts in GvHD there's a shift going on in how children with the illness are stratified. They are all given 7 days of steroids and then two inflammatory biomarkers are checked. If the combined results of those two biomarkers are above a threshold value, they predict a mortality rate of 90%. In other words, the highest risk patients can now be identified and separated out with laboratory tests. And analysis of rem-L data for children "closely matched" to the 90% group, shows that mortality rated can be dropped to 36%. It's detailed in the company's October 17, 2021 PR and in the journal review article by Kasikis et al detailing work being done at Mt Sinai. That's why Dr. Kurtzberg and leading experts in the field are not willing to subject children to a placebo controlled trial. For every 100 children with those high-risk parameters of severe illness, a placebo sentences (90-36=) 54 of them to certain death. That's over half. This one should be a "no-brainer" for the FDA once the "well-established" resolution process eventually plays itself out

    Aloha.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.10
Change
0.020(1.86%)
Mkt cap ! $1.238B
Open High Low Value Volume
$1.08 $1.10 $1.07 $2.839M 2.619M

Buyers (Bids)

No. Vol. Price($)
2 563 $1.10
 

Sellers (Offers)

Price($) Vol. No.
$1.10 131413 27
View Market Depth
Last trade - 14.11pm 21/05/2024 (20 minute delay) ?
Last
$1.09
  Change
0.020 ( 1.89 %)
Open High Low Volume
$1.09 $1.10 $1.07 496653
Last updated 14.29pm 21/05/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.